Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06749457 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
A Phase 1 study of Staphylococcus Aureus, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 231
- Enrollment target
- 20
- Study locations
NCT06749457: Recruiting Phase 1 study of Staphylococcus Aureus, sponsored by AstraZeneca.
NCT06749457 is a Phase 1 study of Staphylococcus Aureus that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 231 participants, below the 3,875-participant average among 8 other Staphylococcus Aureus trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06749457, a Phase 1 study of Staphylococcus Aureus, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 231 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).
Primary Outcome
To evaluate the safety of AZD7760 administered as a single intravenous (IV) Dose A, B, or C.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AZD7760
Study Locations (20)
California
- Research Site - Chula Vista
- Research Site - Chula Vista
- Research Site - Glendale
- Research Site - Granada Hills
- Research Site - Los Angeles
- Research Site - Northridge
- Research Site - Northridge
- Research Site - Oxnard
- Research Site - Riverside
- Research Site - San Dimas
- Research Site - Tarzana
- Research Site - Valencia
- Research Site - Victorville
Florida
- Research Site - Bradenton
- Research Site - Coral Springs
- Research Site - Hollywood
- Research Site - Orlando
- Research Site - Tampa
Alabama
- Research Site - Huntsville
Colorado
- Research Site - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2024-12-30 |
| Est. Completion | 2027-07-06 |
| Phase | Phase 1 |
What NCT06749457 shows while recruiting
NCT06749457 is an interventional study that assigns participants to a tested intervention. The registered 231 participants enrollment target is mid-sized for trials with a published cap, below the 3,875-participant average among 8 other Staphylococcus Aureus trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Staphylococcus Aureus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06749457 names 20 study sites across 4 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06749457 about?
NCT06749457 is a clinical study titled "A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)". The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).
What is the current status of trial NCT06749457?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 231 participants. The study started on 2024-12-30. Estimated completion is 2027-07-06.
What conditions does trial NCT06749457 study?
This clinical trial studies the following conditions: Staphylococcus Aureus.
What interventions are being tested in trial NCT06749457?
The interventions under investigation include: Placebo (OTHER), AZD7760 (DRUG).
Who is sponsoring clinical trial NCT06749457?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06749457 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Staphylococcus Aureus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06749457's enrollment target sits among peer trials
231 3rd of 8 higher than 6 of 8 other Staphylococcus Aureus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Staphylococcus Aureus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome
RECRUITING · Phase 1
-
Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
COMPLETED · Phase 1
-
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
RECRUITING · Phase 4
-
Risk Factors for Linezolid Resistance in Staphylococcus Aureus
COMPLETED
-
A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04077099 · 231 participants · Phase 1
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
- NCT05019495 · 231 participants · NA
Optimizing Tobacco Treatment Delivery for People Living With HIV
- NCT06023589 · 231 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- NCT06734351 · 231 participants · Phase 3
A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI